Judge's Early Ruling May Shape Outcome In Ozempic, Wegovy Lawsuits
Judge's Early Ruling May Shape Outcome In Ozempic, Wegovy Lawsuits
U.S. District Judge Karen Marston of Philadelphia recently issued a pivotal ruling in a closely watched multidistrict litigation (MDL) involving diabetes and weight-loss drugs.
费城的美国地方法官Karen Marston最近在一起备受关注的关于糖尿病和减肥药物的多地法院集中诉讼中作出了具有里程碑意义的裁决。
The litigation focuses on alleged side effects of medications such as Ozempic, Wegovy, and Mounjaro, developed by Novo Nordisk A/S (NYSE:NVO) and Eli Lilly And Co (NYSE:LLY).
该诉讼集中于诺和诺德斯克公司（纽交所：NVO）和礼来公司（纽交所：LLY）开发的Ozempic、Wegovy和Mounjaro等药物的所谓副作用。
Also Read: Novo Nordisk Does Not Operate As Drug Cartel, CEO Defends US Pricing Of Ozempic Against Criticism Over High Drug Prices.
此外还有报道称：新秋叶公司并不像一个药物卡特尔，首席执行官为零售高昂的奥泽匹克辩护。
The ruling centers on the defendants' request to address several key legal questions at the outset of the case, which could potentially streamline or even halt the litigation before it gains momentum.
该裁决集中于被告方在案件初期提出解决几个关键法律问题的请求，这有可能在诉讼获得动力之前压缩或甚至停止诉讼。
Reuters highlights that the plaintiffs in the MDL allege that these medications caused gastroparesis, a condition where the stomach's ability to pass food to the small intestines slows or stops.
路透社强调，诉讼集中于原告声称这些药物导致胃轻瘫，这是一种胃部将食物传送到小肠放慢或停止的情况。
Plaintiffs claim that the drug labels did not adequately warn of this risk. However, Novo Nordisk and Eli Lilly contend that their labels disclose gastrointestinal side effects, including nausea and vomiting.
原告声称药物标签未充分警告这种风险。然而，诺和诺德斯克和礼来公司主张药物标签披露了包括恶心和呕吐在内的胃肠道副作用。
They argue that if plaintiffs cannot definitively prove they suffer from gastroparesis rather than other gastrointestinal issues, their claims should be pre-empted by the existing warnings.
他们认为，如果原告不能明确证明他们患有胃轻瘫而不是其他胃肠道问题，他们的诉讼应受到现有警告的限制。
The judge emphasized that these legal questions could be resolved without hearing from individual plaintiffs. This ruling could significantly impact the trajectory of the case, especially if it leads to dismissing claims or narrowing the issues to be litigated.
法官强调，这些法律问题可以在不听取个体原告陈述的情况下得到解决。这一裁决可能对案件的进展轨迹产生重大影响，尤其是如果导致撤销或限制要诉讼的问题。
Plaintiffs' lawyers argued that it is premature to address these questions without a full factual record from bellwether trials.
原告律师们认为，在没有来自先例审判的完整事实记录的情况下，讨论这些问题为时过早。
They expressed concern that Marston's early rulings might set a precedent that limits plaintiffs' ability to present individual circumstances.
他们表达了对马斯顿早期裁决可能设立先例，限制原告陈述个体情况能力的担忧。
An Eli Lilly spokesperson welcomed the ruling, stating that it would "accelerate resolution" of what the company views as meritless lawsuits.
礼来发言人对裁决表示欢迎，并表示这将“加速解决”公司视为无根据的诉讼。
As the case progresses, legal experts will be closely watching to see how this unusual approach influences the outcome, potentially setting a new standard for future MDLs.
随着案件的进展，法律专家将密切关注这种飞凡手段对结果的影响，可能为未来MDLs设立新标准。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免责声明：本内容部分使用人工智能工具生成，并经Benzinga编辑审核发布。
- Mpox Vaccine: Emergent BioSolutions' Smallpox Vaccine Gets FDA Nod For Expanded Use For Individuals At High Risk Of Mpox Infection.
- Mpox生物-疫苗：Emergent BioSolutions的天花生物-疫苗获得FDA批准，扩大了对高危Mpox感染个体的使用。
Image By Natalia Varlei On Shutterstock
图片来自Natalia Varlei的Shutterstock